Trial Profile

MOdern Treatment of Inhibitor-PositiVe PATiEnts With Haemophilia A - An International Observational Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emicizumab (Primary) ; Eptacog alfa (Primary) ; Factor VIII inhibitor bypassing fraction (Primary) ; Factor VIII/von Willebrand factor (Primary) ; Simoctocog alfa (Primary)
Indications Haemophilia A
Focus Therapeutic Use
Acronyms MOTIVATE

10 Jun 2024 According to an Octapharma media release, data from the study will be presented at the upcoming ISTH 2024 Congress
06 Jun 2023 According to Octapharma media release, Coordinating investigators, Dr Carmen Escuriola Ettingshausen and Robert F.Sidonio Jr., will provide an update on this study status at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) on June 24-28, 2023, in Montreal, Canada.
28 May 2021 According to a media release, the study is supported by funding from Octapharma AG. Full logistical support from a contract research organisation (CRO) is available to all centers.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com